Table of Content

1. INTRODUCTION
1.1. Market Definition
1.2. Market Segmentation


2. RESEARCH METHODOLOGY
2.1. Research Data
2.2. Assumptions


3. EXECUTIVE SUMMARY
3.1. Research Highlights


4. MARKET DYNAMICS
4.1. Market Drivers
4.2. Market Restraints
4.3. Porter’s Five Force Analysis
4.3.1. Bargaining Power of Suppliers
4.3.2. Bargaining Power of Buyers
4.3.3. Threat of New Entrants
4.3.4. Threat of Substitutes
4.3.5. Competitive Rivalry in the Industry
4.4. Industry Value Chain Analysis


5. GLOBAL ANTIBODY-DRUG CONJUGATES MARKET, BY PRODUCT TYPE
5.1. Introduction?
5.2. Adcetris
5.3. Kadcyla
5.4. Other Product Types


6. GLOBAL ANTIBODY-DRUG CONJUGATES MARKET, BY TARGET TYPE
6.1. Introduction?
6.2. CD30 Antibodies
6.3. HER2 Antibodies
6.4. Others?


7. GLOBAL ANTIBODY-DRUG CONJUGATES MARKET, BY TECHNOLOGY?
7.1. Introduction?
7.2. Cleavable Linker
7.3. Non-cleavable Linker


8. GLOBAL ANTIBODY-DRUG CONJUGATES MARKET, BY APPLICATION
8.1. Introduction?
8.2. Breast Cancer
8.3. Blood Cancer
8.4. Ovarian Cancer
8.5. Lung Cancer
8.6. Brain Tumor
8.7. Others


9. GLOBAL ANTIBODY-DRUG CONJUGATES MARKET, BY END-USER
9.1. Introduction
9.2. Hospitals?
9.3. Clinics
9.4. Others?


10. GLOBAL ANTIBODY-DRUG CONJUGATES MARKET, BY GEOGRAPHY
10.1. Introduction
10.2. North America
10.2.1. United States
10.2.2. Canada
10.2.3. Mexico
10.3. South America
10.3.1. Brazil
10.3.2. Argentina
10.3.3. Others
10.4. Europe
10.4.1. United Kingdom?
10.4.2. Germany
10.4.3. France
10.4.4. Spain?
10.4.5. Others
10.5. Middle East and Africa
10.5.1. Saudi Arabia
10.5.2. UAE
10.5.3. Others
10.6. Asia Pacific
10.6.1. China
10.6.2. Japan
10.6.3. South Korea
10.6.4. India
10.6.5. Others


11. COMPETITIVE INTELLIGENCE
11.1. Major Players and Strategy Analysis
11.2. Emerging Players and Market Lucrativeness
11.3. Mergers, Acquisition, Agreements, and Collaborations
11.4. Vendor Competitiveness Matrix


12. COMPANY PROFILES?
12.1. AstraZeneca
12.2. Pfizer, Inc
12.3. Seagen, Inc.
12.4. GlaxoSmithKline Plc
12.5. Takeda Pharmaceutical Company Ltd.
12.6. F. Hoffmann-La Roche Ltd.
12.7. Novartis AG
12.8. Gilead Sciences, Inc.
12.9. Sanofi S.A.
12.10. Astellas Pharma
12.11. Daiichi Sankyo Company Ltd.
12.12. Seattle Genetics Inc.
12.13. Genentech Inc.
12.14. Immunogen Inc.
12.15. Progenics Pharmaceuticals Inc.
12.16. Bayer Healthcare Pharmaceuticals
12.17. Agensys, Inc.
12.18. Synthon Holding B.V.